Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan
· Delayed Price · Currency is TWD 29.95
-0.90 (-2.92%)
Mar 10, 2026, 12:39 PM CST
Advagene Biopharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 18.18 | 52.82 | 65.19 | 18.01 | 14.33 | 121.89 | Upgrade
|
| Short-Term Investments | 149.5 | 149.5 | 60 | 85 | 209.5 | 130 | Upgrade
|
| Trading Asset Securities | - | - | - | - | - | 21.6 | Upgrade
|
| Cash & Short-Term Investments | 167.68 | 202.32 | 125.19 | 103.01 | 223.83 | 273.49 | Upgrade
|
| Cash Growth | 73.70% | 61.61% | 21.54% | -53.98% | -18.16% | 14.91% | Upgrade
|
| Other Receivables | 22.49 | 21.96 | 20.27 | 19.2 | 16.59 | 18.71 | Upgrade
|
| Receivables | 22.49 | 21.96 | 20.27 | 19.2 | 16.59 | 18.71 | Upgrade
|
| Prepaid Expenses | 0.66 | 0.54 | 0.95 | 3.61 | 3.57 | 1.94 | Upgrade
|
| Total Current Assets | 190.83 | 224.82 | 146.41 | 125.82 | 244 | 294.14 | Upgrade
|
| Property, Plant & Equipment | 5.93 | 6.89 | 1.04 | 3.22 | 5.41 | 7.91 | Upgrade
|
| Other Intangible Assets | - | - | - | 9.81 | 9.02 | 13.73 | Upgrade
|
| Other Long-Term Assets | 0.5 | 0.5 | 0.48 | 1.98 | 1.98 | 0.48 | Upgrade
|
| Total Assets | 197.26 | 232.21 | 147.93 | 140.84 | 260.41 | 316.26 | Upgrade
|
| Accounts Payable | 1.66 | 0.75 | 0.87 | 0.56 | 0.56 | 0.56 | Upgrade
|
| Accrued Expenses | 3.97 | 4.7 | 5.99 | 6.05 | 5.79 | 10.16 | Upgrade
|
| Current Portion of Leases | 0.4 | 1.26 | - | 1.35 | 1.27 | 1.23 | Upgrade
|
| Other Current Liabilities | 0.17 | 0.4 | 1.11 | 0.46 | 0.65 | 0.58 | Upgrade
|
| Total Current Liabilities | 6.19 | 7.11 | 7.97 | 8.42 | 8.27 | 12.53 | Upgrade
|
| Long-Term Leases | 3.61 | 4.56 | - | 0.65 | 2.57 | 4.4 | Upgrade
|
| Total Liabilities | 9.8 | 11.67 | 7.97 | 9.08 | 10.84 | 16.93 | Upgrade
|
| Common Stock | 593.8 | 593.8 | 533.8 | 493.49 | 492.92 | 445.42 | Upgrade
|
| Additional Paid-In Capital | - | 90 | 60.39 | 3.12 | 95.12 | 5.06 | Upgrade
|
| Retained Earnings | -406.35 | -463.26 | -454.22 | -364.85 | -338.47 | -247.73 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | - | 96.57 | Upgrade
|
| Shareholders' Equity | 187.46 | 220.54 | 139.96 | 131.76 | 249.57 | 299.33 | Upgrade
|
| Total Liabilities & Equity | 197.26 | 232.21 | 147.93 | 140.84 | 260.41 | 316.26 | Upgrade
|
| Total Debt | 4.01 | 5.82 | - | 2.01 | 3.84 | 5.63 | Upgrade
|
| Net Cash (Debt) | 163.68 | 196.5 | 125.19 | 101 | 220 | 267.87 | Upgrade
|
| Net Cash Growth | 80.44% | 56.96% | 23.95% | -54.09% | -17.87% | 12.54% | Upgrade
|
| Net Cash Per Share | 2.84 | 3.60 | 2.48 | 2.05 | 4.51 | 6.04 | Upgrade
|
| Filing Date Shares Outstanding | 59.38 | 59.38 | 53.38 | 49.35 | 49.29 | 44.54 | Upgrade
|
| Total Common Shares Outstanding | 59.38 | 59.38 | 53.38 | 49.35 | 49.29 | 44.54 | Upgrade
|
| Working Capital | 184.64 | 217.72 | 138.44 | 117.39 | 235.72 | 281.61 | Upgrade
|
| Book Value Per Share | 3.16 | 3.71 | 2.62 | 2.67 | 5.06 | 6.72 | Upgrade
|
| Tangible Book Value | 187.46 | 220.54 | 139.96 | 121.95 | 240.55 | 285.6 | Upgrade
|
| Tangible Book Value Per Share | 3.16 | 3.71 | 2.62 | 2.47 | 4.88 | 6.41 | Upgrade
|
| Machinery | 1.34 | 1.21 | 1.36 | 1.4 | 3.09 | 5.27 | Upgrade
|
| Leasehold Improvements | - | - | - | - | - | 2.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.